Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by Wino115on May 25, 2023 10:01pm
173 Views
Post# 35465069

RE:RE:AACR Poster - very interesting

RE:RE:AACR Poster - very interestingThey got all the data together for the new protocal and the Scientific Adv Committee review and decision on whether to proceed and how. Typically you'd compile for a paper, but perhaps since they had to compile it all for the revision, FDA and that SAC, that is the data the investigator decided to publish and talk about.  I was certain they would only cover the first part of the trial since that followed the procedures and they had 100% of the data from it.  I thougth they'd skip the second part since it was partial data and then just do one more after that data was fully gathered.  So this is a surprise to me that they are reviewing all 38 patients that were on it for a few cycles. Will be really interesting to see the data now just to see what they are basing their decisions on. 
<< Previous
Bullboard Posts
Next >>